Polarean Imaging Exceeds FY24 Revenue Targets and Expands Global Reach

The latest announcement is out from Polarean Imaging ( (GB:POLX) ).

Polarean Imaging has reported a significant increase in its FY24 unaudited revenue, reaching between $3.0 million and $3.1 million, surpassing its revenue guidance. The company has expanded its customer base for the Xenon MRI platform and increased sales of its proprietary Xenon gas blend cylinders by over 50%. A key development is the signing of a distribution agreement with Sumtage in Taiwan, marking Polarean’s first step towards international commercialization. With a strengthened sales team and strategic partnerships, Polarean is well-positioned for further growth in 2025.

More about Polarean Imaging

Polarean Imaging is a medical imaging technology company focused on revolutionizing pulmonary medicine through advanced MRI technology. The company specializes in the development and commercialization of the XENOVIEW MRI platform, which includes a hyperpolarized Xenon MRI contrast agent, gas hyperpolarization system, and associated software and accessories. Polarean aims to address the unmet medical needs of patients with chronic respiratory diseases by providing non-invasive and radiation-free imaging solutions.

YTD Price Performance: 5.00%

Average Trading Volume: 15,725

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $20.63M

For detailed information about POLX stock, go to TipRanks’ Stock Analysis page.